Time to end treatment restrictions for people with hepatitis C who inject drugs

doi:10.1016/S2468-1253(18)30001-3

Comment

. 2018 Mar;3(3):142-143.

doi: 10.1016/S2468-1253(18)30001-3. Epub 2018 Jan 6.

Time to end treatment restrictions for people with hepatitis C who inject drugs

Elana S Rosenthal¹, Sarah Kattakuzhy¹, Shyam Kottilil²

Affiliations

¹ Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
² Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: skottilil@ihv.umaryland.edu.

PMID: 29310927
DOI: 10.1016/S2468-1253(18)30001-3

Comment

Time to end treatment restrictions for people with hepatitis C who inject drugs

Elana S Rosenthal et al. Lancet Gastroenterol Hepatol. 2018 Mar.

. 2018 Mar;3(3):142-143.

doi: 10.1016/S2468-1253(18)30001-3. Epub 2018 Jan 6.

Authors

Elana S Rosenthal¹, Sarah Kattakuzhy¹, Shyam Kottilil²

Affiliations

¹ Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
² Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: skottilil@ihv.umaryland.edu.

PMID: 29310927
DOI: 10.1016/S2468-1253(18)30001-3

No abstract available

PubMed Disclaimer

Comment on

Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, Amin J, Bruneau J, Hellard M, Litwin AH, Marks P, Quiene S, Siriragavan S, Applegate TL, Swan T, Byrne J, Lacalamita M, Dunlop A, Matthews GV, Powis J, Shaw D, Thurnheer MC, Weltman M, Kronborg I, Cooper C, Feld JJ, Fraser C, Dillon JF, Read P, Gane E, Dore GJ; SIMPLIFY Study Group. Grebely J, et al. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6. Lancet Gastroenterol Hepatol. 2018. PMID: 29310928 Clinical Trial.

Cited by

Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic.
Losikoff P, Bosse JD, Martin SA, Wilson A, Chiodo LM. Losikoff P, et al. Front Psychiatry. 2022 Sep 14;13:932306. doi: 10.3389/fpsyt.2022.932306. eCollection 2022. Front Psychiatry. 2022. PMID: 36186876 Free PMC article.
The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study.
Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, Leung J, Grebely J, Larney S, Martin NK, Hickman M, Degenhardt L, May MT, Vickerman P. Trickey A, et al. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):435-444. doi: 10.1016/S2468-1253(19)30085-8. Epub 2019 Apr 10. Lancet Gastroenterol Hepatol. 2019. PMID: 30981685 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Time to end treatment restrictions for people with hepatitis C who inject drugs

Affiliations

Time to end treatment restrictions for people with hepatitis C who inject drugs

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical